Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED Racks Up 1st Out-Licensing Cases in Drug Discovery Support Initiative
March 30, 2017
- Chuikyo Gives Ex-Post Nod to Opdivo’s Optimal Use Guidelines for Head-and-Neck Cancer
March 30, 2017
- CDISC-Based Electronic Submissions for 19 Products Since October: PMDA
March 29, 2017
- MHLW Seeks Cooperation for Sovaldi’s PMS for Genotype 3-6 Use
March 28, 2017
- Promotion Plan for Cancer Genomics Due Out This Summer
March 28, 2017
- MHLW Issues Optimal Use Guidelines for Opdivo Following Approval of Add’l Indication for Head and Neck Cancer
March 28, 2017
- MHLW Orders Label Revisions for Lamictal, Zione
March 27, 2017
- Orphan Designation Granted for Olaparib, 3 Other Drugs
March 27, 2017
- Cabinet OKs PMDA’s Review Fee Raise from April 1
March 27, 2017
- MHLW OKs Sovaldi for Genotypes 3-6, Opdivo for Head and Neck Cancer
March 27, 2017
- MHLW Poised to Review System Designs to Prevent Counterfeits: Minister
March 24, 2017
- No Extra Fees Will Be Charged for Add’l Survey Items for MID-NET’s PMS Use: MHLW Working Group
March 23, 2017
- Clinical Research Bill Passes Lower House
March 23, 2017
- MHLW Orders Label Revisions for 44 APIs in Sleep/Anxiolytic/Epilepsy Agents
March 21, 2017
- MHLW Unveils Revised Label Format; Notification Due Out Early FY2017
March 21, 2017
- MHLW Ordinance Will Close Loopholes in Clinical Research Bill’s Funding Disclosure Rules: Bureau Chief
March 21, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Japan Healthcare Spending Logs Slight Rise on Subdued Hep C Sales in April-September
March 17, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Recovering Trust in Clinical Research Is Urgent Task: Shiozaki
March 17, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…